Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush lifted their Q2 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued to clients and investors on Tuesday, May 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.51) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at $0.16 EPS, FY2026 earnings at ($2.82) EPS, FY2027 earnings at ($2.94) EPS, FY2028 earnings at ($2.53) EPS and FY2029 earnings at ($1.89) EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. HC Wainwright dropped their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and an average price target of $23.20.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $9.63 on Friday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The firm has a market capitalization of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.20. The stock’s 50-day simple moving average is $8.12 and its 200-day simple moving average is $9.99.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after buying an additional 5,084 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $63,000. AlphaQuest LLC purchased a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $72,000. US Bancorp DE increased its stake in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after purchasing an additional 11,108 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Stoke Therapeutics in the 1st quarter worth about $92,000.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.